Aberdeen Group
ABVX

Aberdeen Group’s Abivax ABVX Stock Holding History

Aberdeen Group’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48M Buy
431,241
+4,583
+1% +$542K 0.08% 222
2025
Q4 		$57.5M Sell
426,658
-360,759
-46% -$39.4M 0.09% 181
2025
Q3 		$66.9M Buy
787,417
+76,901
+11% +$4.71M 0.11% 159
2025
Q2 		$5.44M Hold
710,516
– – 0.01% 695
2025
Q1 		$4.44M Buy
710,516
+286,335
+68% +$1.94M 0.01% 693
2024
Q4 		$3.11M Buy
424,181
+107,750
+34% +$992K 0.01% 711
2024
Q3 		$3.65M Buy
316,431
+198,225
+168% +$2.38M 0.01% 698
2024
Q2 		$1.56M Buy
+118,206
New +$1.69M ﹤0.01% 781

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Aberdeen Group's ABVX Position: Q1 2026 in Review

Aberdeen Group increased its Abivax (ABVX) stake by 1.1% in Q1 2026, buying an estimated $542K and bringing the position to 431,241 shares worth $48M. The position accounts for 0.08% of the portfolio, ranked #222.

Aberdeen Group first reported a position in ABVX in Q2 2024 and has held it in 8 quarters since. The position peaked at $66.9M in Q3 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Aberdeen Group held 431,241 shares of Abivax worth $48M as of Q1 2026.
  • Aberdeen Group bought 4,583 Abivax shares in Q1 2026, an estimated $542K.
  • Abivax made up 0.08% of Aberdeen Group's portfolio in Q1 2026, its #222 holding.
  • Aberdeen Group first reported a position in Abivax in Q2 2024 and has held it in 8 quarters since.
  • Aberdeen Group's Abivax position peaked at $66.9M in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.